Pharmaceutical developer ImaRx Therapeutics said that it has received a $1.1 million phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH).
The grant money is for the development of targeted nanobubbles that can be used in conjunction with ultrasound for the treatment of vascular clots, according to the Tucson, AZ-based firm. As a part of the NHLBI grant, the company will develop new nanobubbles for targeted thrombus treatment in patients suffering from myocardial infarction.
Under the terms of the grant, ImaRx will collaborate under a subcontract with cardiologist Dr. Thomas Porter of the University of Nebraska Medical Center to test the nanobubbles with ultrasound in models of myocardial infarction. In addition, Flemming Forsberg, Ph.D., a professor in the department of radiology at Thomas Jefferson University in Philadelphia, will perform in vitro ultrasound studies of ImaRx's targeted nanobubbles in conjunction with ultrasound.
By AuntMinnie.com staff writers
August 2, 2005
Related Reading
ImaRx's SonoLysis begins phase I/II PAOD trial, April 12, 2005
ImaRx initiates SonoLysis phase II stroke trial, April 5, 2005
ImaRx raises $7 million, March 10, 2005
ImaRx, Guerbet in MR molecular imaging deal, December 10, 2004
ImaRx completes private placement, names chairman, April 2, 2004
Copyright © 2005 AuntMinnie.com
